Sign up to save your podcasts
Or
Share For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival
Oncology Times Broadcast News
For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival
Charles Coombes at ECCO15-ESMO34 on the Intergroup Exemestane Study showing a big increase in survival for patients with early breast cancer randomized to have their adjuvant therapy switched to exemestane after 2-3 years of tamoxifen, compared with those who remained on tamoxifen for the entire 5 years of endocrine therapy.
View all episodes
By Oncolgy Times & Audio Medica
2.3
33 ratings
Oncology Times Broadcast News
For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival
Charles Coombes at ECCO15-ESMO34 on the Intergroup Exemestane Study showing a big increase in survival for patients with early breast cancer randomized to have their adjuvant therapy switched to exemestane after 2-3 years of tamoxifen, compared with those who remained on tamoxifen for the entire 5 years of endocrine therapy.